Consider reducing concomittant suphonylurea dose.
Concurrent insuln ,D-phenylalamine b derivatives, megalitinides, alpha- glucosidase inhibitors
 not recommended

Hypoglycemia possible with sulponylurea.
May delay absorption of oral drugs ( take these one hour before exenatide )

Monitor warfarin
Prandial glucose  regulators

Statins
Drugs affected by change in rate of gastric emptying

GI upset, hypoglycemia, dizziness, headache, asthenia,
Reduced appitite, weight loss, GERD,

Hyperhidrosis, antibody formation
( glycemic response may be attenuated  )

Suspect acute pancreatitis if persistent severe abdominal pain with/without vomiting )
Altered kidney function.

Injection site reactions
Renal insufficiency,

Acute renal failure
Sports events -restricted/banned

Type II diabetes.
Type II diabetes with beta cell failure
Severe renal impairment

Severe gastro-intestinal disease
Diabetic ketoacidosis
Postprandial administration     

Pregnancy
Lactation    


Special precautions-

Not a subtitute for insulin
Moderate renal impairment
Elderly

Type II diabetes  mellitus in combination with metformin

Given by sc inj into thigh, abdomen or upper arm with 60 minutes before AM and Pm meals
initially 5mcg twice daily
May increase to 10mcg twice daily after one month

Not recommended for patients below 18 years

Contraindicated for use during pregnancy and lactation
Observe caution